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Robust SNP genotyping technologies and data analysis programs have encouraged researchers in recent years to use SNPs for linkage
studies. Platforms used to date have been 10 K chip arrays, but the possible value of interrogating SNPs at higher densities has been con-
sidered. Here, we present a genome-wide linkage analysis by means of a 500 K SNP platform. The analysis was done on a large pedigree
affected with Parkinsonian-pyramidal syndrome (PPS), and the results showed linkage to chromosome 22. Sequencing of candidate
genes revealed a disease-associated homozygous variation (R378G) in FBXO7. FBXO7 codes for a member of the F-box family of proteins,
all of which may have a role in the ubiquitin-proteosome protein-degradation pathway. This pathway has been implicated in various
neurodegenerative diseases, and identiﬁcation of FBXO7 as the causative gene of PPS is expected to shed new light on its role. The per-
formance of the array was assessed and systematic analysis of effects of SNP density reduction was performed with the real experimental
data. Our results suggest that linkage in our pedigree may have been missed had we used chips containing less than 100,000 SNPs across
the genome.Genome-wide linkage analyses of Mendelian diseases have
traditionally been done with microsatellite markers.1,2 The
potential value of using single-nucleotide polymorphisms
(SNPs) in such analysis has been more recently pro-
posed.3–7 Their advantages largely stem from their higher
density and global distribution in the human genome.
Robust SNP genotyping technologies and data analysis
programs have encouraged researches to use SNP platforms
in linkage studies.8–12 Platforms used to date have been
10 K chip arrays; however, the possible value of interrogat-
ing SNPs at a higher density in linkage analysis has been
considered.11,13 Here, we present what is to the best of
our knowledge the ﬁrst genome-wide linkage analysis
with a 500 K SNP platform. The analysis was performed
on a large Iranian pedigree affected with Parkinsonian-py-
ramidal syndrome (PPS [MIM 260300]; Figure 1). It resulted
in the identiﬁcation of FBXO7 as the likely disease-causing
gene. The performance of the array was assessed and sys-
tematic analysis of effects of SNP density reduction on in-
formation content, maximum LOD scores, and length of
linked area was performed.We surmised that for our partic-
ular pedigree structure, linkage may well have been missed
had we used chips containing less than 100,000 SNPs.
PPS is a hypokinetic rigid disorder, the most common
example of which is Parkinson’s disease.14 PPS is a rare dis-
order that exhibits both Parkinsonian and pyramidal-asso-
ciated symptoms. Approximately 20 patients have been
reported in the literature.14–17 Symptoms, which may be
vague in the beginning, start in young adulthood, progress
relatively slowly, and may culminate in severe movementThe Amincapacity. Response to levadopa is usually dramatic and
sustained for many years. Most, but not all, reported cases
have been familial and associated with parental consan-
guinity, suggesting autosomal-recessive inheritance.14,16,18
The research was performed in accordance with the Hel-
sinki Declaration and with approval of the ethics boards of
the University of Tehran. All participants consented to par-
ticipate after being informed of the nature of the research.
Living members of the PPS pedigree were examined by two
movement-disorder specialists, and many were also exam-
ined by specialists in other ﬁelds. Ten individuals dispersed
in two generations were assessed to be affected with PPS
(Figure 1). An 11th individual (5043) was assessed as having
been affected based on phenotypic features reported by
family members. All other living members of the pedigree
were assessed to be normal.
Clinical information on the ten affected individuals is
presented in Table 1. All affecteds exhibited equinovarus
deformity since childhood, which is usually indicative of
a genetic central nervous system disorder.19 None had
symptoms associated with cerebellar malfunction. All ex-
hibited Babinski signs, spasticity, and hyperactive DTR.
The Babinski signs in all were initially unilateral, and later
became bilateral. Spasticity was restricted to lower limbs in
most patients. Onset of pyramidal symptoms in the pa-
tients was always in the third decade of life. At the time
of writing, detectable extrapyramidal symptoms have
evolved only in the three most severely affected individ-
uals (5001, 5003, and 5027). These symptoms became
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Figure 1. Parkinsonian-Pyramidal Syndrome Pedigree
Affected individuals are shown by shading. All individuals with number ID were included in pedigree file imported into MERLIN. Only
living individuals whose ID numbers start with 5 were genotyped on the chips. Individuals 5042 and 5043 and individuals 5049 and
4106 were each reported to be distally related, but consanguinity between the individuals is not indicated because the exact relationship
between the individuals could not be ascertained. The dashed line delineates the margin between the two minimized pedigrees.symptoms. The extrapyramidal symptoms of patient 5027
were rapidly alleviated by L-dopa, and the response has
been sustained for 4 years. Patients 5001 and 5003 were
not cooperative in receiving treatment. None of the pa-
tients exhibited tremor, upgaze paresis, Myerson’s sign,
or dementia. Brain and spinal MRI, EEG, ocular examina-
tion, and EMG were performed on individuals 5001,
5027, and 5030; the results were normal. A complete labo-
ratory metabolic workup on these patients, which in-
cluded measurement of serum ceruloplasmin and copper
level, did not show any biochemical abnormality. Move-
ment anomalies and some other features of affected indi-
viduals are evident in video recordings and photograph
(see Movies S1–S4 and Figure S1 available online). Reasons
by which diseases other than Parkinsonian-pyramidal
syndrome were excluded are given in Table S2.
Genomic DNA was prepared from venous blood of 10
affected and 14 unaffected members of the pedigree.1376 The American Journal of Human Genetics 82, 1375–1384, JuneGenome-wide linkage scan was performed on these
DNAs with the GeneChip Human Mapping 500K Array
Set according to the manufacturer’s recommended proto-
col (Affymetrix, Santa Clara, CA). Arrays were processed
through Affymetrix microﬂuidics stations, and images
were obtained with an Affymetrix Gene Array scanner.
Raw microarray feature intensities were processed with
GeneChip Genotyping Analysis Software v.4.1.0.26
(GTYPE) to derive SNP genotypes. GTYPE uses the Bayes-
ian Robust Linear Model with Mahalanobis distance classi-
ﬁer (BRLMM) algorithm for genotype calling.
SNP call rate with BRLMM for the 24 individuals tested
ranged from 98.12% to 99.62% and was 99.15% on the
average. Across all genotype calls of all individuals, 26%
(range 25%–27%) were heterozygous. Concordance of
the genotypes of the 50 SNPs shared on the two arrays of
the 24 individuals genotyped was 99.76%. On the average,
0.58% of 10,524 X chromosome SNPs were genotyped asTable 1. Clinical Features of Affected Individuals
Extrapyramidal Symptoms Pyramidal Symptoms
Rigidity Bradykinesia Hypomimia
Monotone
Speech
Babinski
Signs Spasticity
Hyperactive
DTR Scissor Gait
Equinovarus
Deformity
5001* þ þ þ þ þ þ þ unable to walk þ
5002 - - - - þ þ þ - þ
5003* þ þ þ unable to speak þ þ þ unable to walk þ
5004 - - - - þ þ þ - þ
5027* þ þ þ þ þ þ þ þ þ
5030 - - - - þ þ þ - þ
5039 - - - - þ þ þ - þ
5049 - - - - þ þ þ - þ
5050 - - - - þ þ þ - þ
5051 - - - - þ þ þ - þ
*The most severely affected individuals.2008
heterozygous in each of the 14 male individuals geno-
typed. Often, the same SNP was miscalled in several male
individuals. Genotypic information was obtained for the
mother (5049) of only four of these male individuals,
and these four were siblings. Approximately 7000 homozy-
gous X chromosome SNPs were observed in this female in-
dividual, and alternate allele genotype calls for these SNPs
in her sons allows for detection of another set of miscalls. It
was estimated that 0.1% of these SNPs were miscalled per
individual in this part of the pedigree. By extrapolation,
the transmission error rate per generation for the entire
data set is expected to be approximately 0.7%. In fact,
GTYPE detectedMendelian errors in 0.06% of the SNPs dis-
persed throughout the genome per individual genotyped.
By comparison with the more telling SNPs of the X chro-
mosome, the ﬁgures suggest that only about 10% of the
miscalls on the autosomal chromosomes are detected.
GTYPE removed SNPs that were detected as Mendelian er-
rors. It subsequently removed 42% of the remaining SNPs
because only one allele for each was observed in our entire
pedigree, or because of a call rate less than 90% among all
the individuals. The number of remaining SNPs was
286,508.
For genetic analysis, an appropriate GTYPE option was
used to automatically export by chromosome genotype
calls into MERLIN.20 Because of the large size of the pedi-
gree, it was split into two smaller pedigrees for analysis
(Figure 1). Individuals 5042 and 5043 were deﬁned as the
ancestors of one of the minimized pedigrees, and indi-
viduals 4103 and 4104 as the ancestors of the other. In-
dividual 5043 was included only in the ﬁrst minimized
pedigree. The PedWipe option in MERLIN assessed 0.3%
(based on chromosome 22 data) of the calls unlikely to
be correct and removed these. MERLIN was then used to
assess information content of the arrays and to perform
multipoint nonparametric (NPL) and parametric linkage
analysis. Inheritance of PPS in affected kindreds has been
proposed to be autosomal recessive, but sporadic cases
have also been reported and the possibility that this condi-
tion may be heterogeneous has been suggested.14–16 The
rarity of the condition, the inbreeding reported in our ped-
igree (especially in generations I, II, and before), and the
absence of disease among individuals of generation IV
are strongly suggestive of an autosomal-recessive mode of
inheritance in this pedigree. On the other hand, the possi-
bility that onset of symptoms had not yet manifested in
some young generation IV individuals, ambiguity of con-
sanguinity between parents of affected individuals, and
the observation of disease in consecutive generations
made it unwise to rule out possible dominant inheritance.
Merlin calculated a nonparametric logarithm of odds
(LOD) score by use of the Kong and Cox exponential
model.21 MERLIN also generated parametric LOD scores
under assumption of disease allele frequency of 0.0001
and full penetrance. Because of limitations of computer
memory, data of three unaffected individuals in generation
IV (individuals 5006, 5011, and 5028) and the unaffectedThe Ammother of one of these (individual 5048) were not included
in the original analysis. The information content and
results of scans for all the chromosomes under the NPL, au-
tosomal-recessive, and autosomal-dominant models based
on data of 20 individuals are shown in Figures S2–S5. After
having focused on chromosome 22, data on all 24 individ-
uals were included for the analysis of this relatively small
chromosome. The average information content for each
of the 23 chromosomes was notable and ranged from
0.948 to 0.996. Maximum potential LOD score calculated
for our pedigree structure by MERLIN under NPL was
4.21 (Z ¼ 9.806; p ¼ 105).20 NPL analysis resulted in
LOD scores of greater-than-suggestive LOD score 2.1 (p <
0.001) on chromosomes 3, 5, 7, 11, 14, 15, and 22, and
LOD scores greater-than-signiﬁcant LOD score of 3.3 (p <
0.00005) on chromosomes 5, 11, 14, and 22.22 Because
the peaks of chromosomes 5, 11, and 14 each included at
most 6 SNPs and covered a maximal range of 0.2 cM, it
was assumed they were probably due to erroneous geno-
typings not detected by the various error-checking proto-
cols. On chromosome 22, a broad region extending from
4.17 to 28.18 cMwas associated with an average LOD score
of 2.90, and another region extending from 34.40 to 41.93
cM (28,934,667 bp–34,951,655 bp) was associated with an
average LOD score of 4.08 (average p ¼ 0.00003) (Fig-
ure 2A). Within the latter region, the maximum predicted
LOD score of 4.21 was observed in region extending from
36.58 to 39.98 cM. Parametric analysis under an autoso-
mal-dominant model resulted in only negative LOD scores
on all chromosomes except 22, on which an average score
of 0.81 was achieved at region extending from 34.40 to
35.97 cM (maximum LOD ¼ 1.57 at 34.57 cM) (Figure 2A).
Finally, analysis under an autosomal-recessive model re-
sulted in positive LOD scores on chromosomes 5 (average
LOD of peak ¼ 3.00), 15 (average LOD ¼ 1.18), and 22.
The region on chromosome 22 was broad and extended
from 30.48 to 56.24 cM; the average associated LOD score
was 2.825 (Figure 2A). Within this region, there was a peak
extending from 34.50 cM to 36.88 cM (29,055,302 bp–
31,414,345 bp), with an average associated LOD score of
3.32. The maximum score achieved within the region
was 3.39. The peak region on chromosome 22 as compared
to the peak region of chromosome 5 was considered a
better candidate region because a signiﬁcantly overlapping
region of chromosome 5 was not observed under the NPL
model. Furthermore, it was observed that the genotypes of
the affected individuals for many of the SNPs in the chro-
mosome 5 region were heterozygous. For example, at the
SNP position associated with the maximum LOD score
(3.38), seven of the ten affected individuals genotyped
were heterozygous. Twenty simulations for each of the
inheritance models by means of the chromosome 22
genotypes resulted in maximum LOD scores of 1.54,
5.87, and 1.08, respectively, for the NPL, autosomal-
dominant, and autosomal-recessive models (not shown).
The information content across the length of chromosome
22 approached 1, and the average was 0.964 (Figure 2B).erican Journal of Human Genetics 82, 1375–1384, June 2008 1377
Figure 2. LOD Plots and Information Content for Chromosome 22
(A) The LOD plots under NPL, autosomal-dominant, and autosomal-recessive models of disease inheritance are shown.
(B) Information content for chromosome 22.Visual inspection, in fact, showed that all affected individ-
uals and only affected individuals shared a homozygous
genotype for all 209 SNPs within the region (2.38 cM) hav-
ing the average LOD value of 3.32. It was surmised that the
locus most likely associated with the disease status was on
chromosome 22 and that its mode of inheritance in the
pedigree was autosomal recessive. Interestingly, results of
haplotyping of chromosome 22 by MERLIN revealed that
one of the recombination events that delimited the linked
region occurred in ﬁve meioses. This event occurred be-
tween rs134176 and rs738996, suggesting a recombination
hotspot. Reanalysis of chromosome 22 data by means of
clusters at r2 values of 0.4 produced NPL, autosomal-dom-
inant, and autosomal-recessive LOD plots nearly identical
to those produced without clustering (not shown).1378 The American Journal of Human Genetics 82, 1375–1384, JuneAnnotations provided by GTYPE and the NCBI database
were used to identify genes within chromosomal regions
that showed linkage. The critical region of 34.50–36.88 cM
on chromosome 22 contains 34 annotated genes. To prior-
itize the region to be examined, we reasoned that the
region containing the causative gene should cause a drop
in LOD score under the dominant model, because at least
nine unaffected individuals were expected to carry one
copy of the disease-causing allele. Furthermore, we
expected the disease-causing gene to be included in the
region associated with a high LOD score under the NPL
model. The right border of the linked region under the
dominant model was at 35.97 cM, and the overlap be-
tween the critical region under the recessive model and
the region having an average LOD score of 4.08 under2008
Figure 3. Prioritization of Linkage to Region of 0.9 cM on Chromosome 22
Regions on chromosome 22 showing maximum linkage to disease phenotype under NPL (34.40–41.93 cM), autosomal-dominant (34.40–
35.97 cM), and autosomal-recessive (34.49–36.88 cM) models are shown as overlapping regions. The solid gray bar (36.00–36.88 cM)
indicates region prioritized for selection of candidate genes.the NPL model extended from 36.00 cM to 36.88 cM
(Figure 3). Four genes are annotated in this region of chro-
mosome 22: ret ﬁnger protein-like 3 (RFPL3), C22orf28
(alias HSPC117), bactericidal/permeability-increasing pro-
tein-like 2 (BPIL2), and F-box protein 7 (FBXO7). Part of
synapsin III (SYN3) also lies within the region, and TIMP
metallopeptidase inhibitor 3 (TIMP3) lies just downstream.
C22orf28, FBXO7 (MIM 605648), SYN3 (MIM 602705),
and TIMP3 (MIM 188826) were considered to be good bio-
logical candidate genes for the disease phenotype of our
pedigree.23–28
The exons and ﬂanking intronic sequences of these four
genes were ampliﬁed from the DNA of patient 5001 by PCR
and subsequently sequencedwith the ABI Big Dye termina-
tor chemistry and an ABI Prism 3700 instrument (Applied
Biosystems, Foster City, CA). Sequences were analyzedwith
the Sequencher software (Gene Codes Corporation, Ann
Arbor, MI) (Table S1). The frequencies of alleles at variant
positions in different populations were obtained from the
HapMap site when available. Predicted effects of variant se-
quences on splicing were determined by comparison with
known canonical splice site motifs by means of NNsplice
0.9 and genescan. For determination of extent of conserva-
tion of amino acids altered due to nucleotide variations
found, the amino acid sequences of homologous proteins
from other species were obtained from NCBI and aligned
with the ClustalW 1.83 software.
Five sequence variations in the homozygous state were
observed in C22orf28, six in FBXO7, three in SYN3, and
none in TIMP3 (Table 2). Except for g.18550C/G in
FBXO7, the observed variations were considered not to
be associated with disease status. They were assessed not
to affect splicing, and most were also reported at relatively
high frequencies in other populations (0.1–0.9).
FBXO7 codes two cDNA and protein isoforms. The iso-
form 1 protein is longer than the isoform 2, but amino
acid 92 to amino acid 522 of the former correspond exactly
to amino acids 7 to 443 of the latter. Because references to
FBXO7 in the literature are generally with respect to iso-
form 1 of the cDNA and protein, we will henceforth
make references with respect to this isoform.29–31 TheThe Amc.1132C/G change results in the nonconservative amino
acid substitution of glycine for arginine at position 378
(R378G) in the F-box protein 7. Arginine at position 378
is completely conserved in all F-box protein 7 proteins se-
quenced, including the protein in species as distally related
as humans and the purple sea urchin (Table S3). Further-
more, it lies within a well-conserved region of the protein
and within a completely conserved -RDF- motif. By se-
quencing, the variant allele was also observed in the ho-
mozygous state in three other affected individuals (5003,
5049, and 5051) and in the heterozygous state in one un-
affected obligate carrier (5005). By an ARMS-PCR target
mutation analysis assay, it was shown that the remaining
six available affected pedigree members each carried two
mutant alleles and that eight obligate carriers each carried
one mutant allele. These data showed segregation of
R367G with the disease phenotype in an autosomal-reces-
sive pattern in the pedigree. The mutant allele was not ob-
served in the chromosomes of 800 control individuals. 600
of the controls were unrelated healthy Iranian individuals
over the age of 60 without self-reported movement or
neurological disorders, and 200 were unrelated Iranians
diagnosed with Parkinson’s disease.
Our results suggest that the mutation causing the R378G
substitution in the FBXO7 protein is the cause of the dis-
ease phenotype exhibiting pyramidal and extrapyramidal
anomalies in our pedigree. The condition was inherited
in an autosomal-recessive fashion. FBXO7 codes for amem-
ber of the F-box family of proteins. F-box proteins all con-
tain an F-box motif, a motif consisting of ~40 amino acids
that is functionally deﬁned as one that can interact with
the Skp1 component of the SCF (Skp1, Cdc53/Cullin1,
F-box) protein complex.30,32–34 FBXO7 also contains a pro-
line-rich region (PRR) that is responsible for binding discs,
large homolog 7 (DLG7, alias HURP), a known substrate of
FBXO7.30 The R378G mutation lies at or near the right
border of the F-box motif and approximately 45 amino
acids upstream of the left border of the PRR motif and
may disrupt the function of either or both of these (Fig-
ure 4). Interactions of FBXO7 with proteins other than
DLG7 have also been reported and it has been suggestederican Journal of Human Genetics 82, 1375–1384, June 2008 1379
Table 2. Sequence Variations
Gene Gene Locationa cDNA Locationb Effect on Proteinc rs Numberd Allele Frequency Ranged,e
C22orf28 g.3571A/G c.172þ77A/G - rs2076044 0.15–0.53
g.3580C/T c.172þ86C/T - rs2076043 0.67–0.90
g.3923C/T c.173-84C/T - rs5754073 0.67–0.90
g.17233T/G c.1179þ10T/G - rs2072818 0.48–0.79
g.20160A/T c.1410þ151T/G - rs5994562 0.09–0.54
FBXO7 g.677T/G c.122þ272T/G 1 p.L12R 2 rs8137714 -
c.35T/G 2
g.736C/A c.122þ331C/A 1 - rs8140067 0.1–22
c.37þ57C/A 2
g.4484G/A c.343G/A 1 p.M115I 1 rs11107 0.36–0.68
c.233G/A 2 p.M36I 2
g.16292T/C c.872-75T/C1 - rs738982 0.36–0.68
c.635-75T/C2
g.16444C/T c.949C/T 1 p.L317L 1 rs9726 0.36–0.68
c.712C/T 2 p.L238L 2
g.18550C/G c.1132C/G 1 p.R378G 1 ss99938574 NA
c.895C/G 2 p.R299G 2
SYN3 g.75518C/A c.461þ209C/A IIIa, IIIc - rs183588 0–0.12
g.477951G/C c.1230þ128G/C IIIa, IIIc - rs135123 0.1–0.19
g.493006C/T c.*1C/T IIIa - ss99938576 NA
c.*118C/T IIIc -
Putative disease-associated variation is shown in bold. NA, not available.
a Gene positions in C22orf28, FBXO7, and SYN3 are, respectively, with reference to sequences NT_011520.11 (nucleotides 12198804-12174138),
NT_011520.11 (nucleotides 12261276-12285387), and NT_011520.11 (nucleotides 12793252-12299109).
b cDNA positions in C22orf28 are with reference to sequence NM_014306.3. cDNA positions in FBXO7 are with reference to sequence NM_012179.3 for
isoform 1 and and sequence NM_001033024.1 for isoform 2. cDNA positions in SYN3 are with reference to sequence NM_003490.2 for isoform IIIa and
sequence NM_133633.1 for isoform IIIc.
c Protein positions in F-box only protein 7 are with reference to sequence NP_036311.3 for isoform 1 and sequence NP_001028196.1 for isoform 2.
Superscripts of cDNA and amino acid variations refer to respective isoforms.
d NCBI Build 36.2 was used to obtain all reference sequences.
e Range of frequency of the varied alleles observed in pedigree reported for populations of HapMap project. No sequence variations were observed in
sequenced regions of gene TIMP3.that some of the effects of FBXO7 are not mediated by
ubiquitin-mediated degradation of the proteins with
which it interacts.35 And, of course, ubiquinitation may
affect cellular functions other than proteolysis.36,37
The role of FBXO7 in neurons is not known. However,
mutations affecting proteins involved in the ubiquitin-
proteolytic pathway have been associated with various
neurodegenerative diseases, including Parkinson’s and
Alzheimer’s diseases, signifying the importance of this
pathway in neuron function.24 Mutations in FBXO7 have
not been observed in any of the aforementioned diseases.
Functional studies need to be performed to conﬁrm and
expand on the genetic ﬁndings reported here.1380 The American Journal of Human Genetics 82, 1375–1384, JunThe analysis performed on our pedigree produced data
that allowed evaluation of the performance of the Affyme-
trix 500 K chips for linkage analysis. Although GTYPE
seems to detect only a small fraction of the SNP miscalls,
the number of miscalls in our analysis was sufﬁciently
low not to preclude detection of linkage in our pedigree.
As reported by others, the PedWipe option in MERLIN
was very effective in removing faulty peaks caused by
one or few SNPs (not shown). Consideration of effect of
linkage disequilibrium (LD) on LOD scores is an issue
when high-density marker platforms are used. However,
this consideration is most important in sib pair analysis
and multipedigree analysis, especially when parentalFigure 4. Schematic View of F-Box Only Protein 7, Isoform 1
Numbers on top indicate amino acid residue positions of left and right borders of F-box and proline-rich regions. The position of putative
disease associated variation is shown below.e 2008
Figure 5. Effects of Reduction of Chromosome 22 SNP Numbers
(A) Effect on maximum LOD scores under NPL and recessive models of inheritance.
(B and C) Effect on position and length of linked area with cut offs of 0.1, 0.3, 0.4, and 0.5 below maximum LOD scores under NPL (B) and
recessive (C) models.
The y axis shows cM along chromosome 22. The horizontal grid shows the 36.00–36.88 cM region.genotypes are not available.4,38–41 The effect is least impor-
tant in linkage analysis by means of a single pedigree, as is
the case in the present study. MERLIN allows for consider-
ation of linkage disequilibrium by use of the Cluster op-
tion. Clustering effectively identiﬁes adjacent markers
that are in LD as a single marker and thus minimizes any
possible effect LD may have on parameter being queried,
i.e., LOD score. As expected, clustering hadminimal effects
on the LOD plots of our analysis.
Having identiﬁed the putative disease-causing gene, we
attempted to ascertain the value of using a dense SNP
map in our analysis under NPL and recessive models by
systematically reducing the number of SNPs (Figures 5
and 6). A program was written in PERL for SNP reduction
that allowed SNP selections starting at designated SNP
and multiplier. The multiplier determines the number ofThe AmSNPs to be removed between consecutive SNPs to be
kept. Linkage analysis was repeated only for chromosome
22 SNPs while reducing the number of SNPs by factors
ranging between 2 and 100. The average information con-
tent was reduced notably (Figure S6) and became uneven
(not shown) across the length of chromosome 22 at greater
than 20-fold reductions. In both models, the maximum
LOD score progressively decreased with reduction in den-
sity of SNPs, but the effect was more pronounced in the
NPL model (Figure 5A). Finally, length of linked region at
greater than 20-fold reductions under the NPL model in-
creased notably and became more sporadic (Figure 5B). A
similar pattern was observed under the recessive model
(Figure 5C). As SNP number reduction increased and cut
off below maximum LOD decreased, it became increas-
ingly probable that the critical region containing FBXO7erican Journal of Human Genetics 82, 1375–1384, June 2008 1381
Figure 6. Effects of Change In-Frame of SNP Reductions
(A) Effect on maximum LOD score. Bars indicate 5 1 standard deviation.
(B) Effect on length of linked region. The linked region is defined by cut off of 0.1 below maximum LOD score.
The y axis shows cM along chromosome 22. The horizontal grid shows the 36.00–36.88 cM region.would not be included in selected region under the NPL
model (Figure 5B). In addition to these effects, at reduc-
tions greater than 20-fold, spurious peaks in other
regions of chromosome 22 were observed (not shown).
The 80-fold and 8-fold reduction of SNPs produce, re-
spectively, platforms comparable to 10 K and 100 K chips.
In order to consider possible consequence of using differ-
ent combination of SNPs, these two levels of reductions
were each performed in several frames (Figure 6). All seven
possible frames for the 8-fold reduction and the ﬁrst seven
frames for the 80-fold reduction were tested. The comple-
ment of SNPs included had minimal effects on informa-
tion content (not shown). The average maximum LOD
score for the 8-fold reductions under the NPL and recessive
models were 3.68 5 0.59 and 3.2 5 0.14, respectively
(Figure 6A). The trend of less variation in maximum LOD
scores under the recessive model was more notable at
80-fold reductions of SNP numbers. The averagemaximum
LOD scores under NPL and recessive models were, respec-
tively, 1.5 5 0.84 and 3.0 5 0.02. Interestingly, the
selected 36.00 cM to 36.88 cM region lies within the linked
region of all 8-fold reduction frames under the recessive
model and within seven of the 8-fold reductions under
the NPL model. Among the ten 80-fold reductions tested,
the gene lies within the linked area in only two frames
under the recessive model and in none under the NPL
model. Linked regions were notably sporadic with 80-fold
reductions under the NPL model (Figure 6B).
Based on these observations, we conclude that for our
pedigree, it may have proved unproductive to use chips
containing less than 100,000 SNPs spread across the
genome. The conclusion may not be valid for all linkage
analysis with single pedigrees, but should be taken into1382 The American Journal of Human Genetics 82, 1375–1384, Juneconsideration because the costs associated with the use of
dense chips has decreased. In linkage analysis with a larger
number of pedigrees, the fraction of SNPs that are uninfor-
mative because of only one allele being observed through-
out the pedigrees is expected to decrease, and chips of less
density may perform adequately in such studies.
Supplemental Data
Six ﬁgures, three tables, and four movies are available at http://
www.ajhg.org/.
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